

## AMENDMENT TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### LISTING OF CLAIMS

Claims 1-286 (canceled)

- 1 ~~287~~. (new) A method of inducing tumor tissue regression in a patient comprising administering to said patient a therapeutically effective amount of an antibody immunospecific for  $\alpha_v\beta_3$ .
- 2 ~~288~~. (new) The method of claim ~~287~~ wherein said antibody is a monoclonal antibody.
- 3 ~~289~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said tissue is a solid tumor tissue.
- 4 ~~290~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said tumor tissue is bladder.
- 5 ~~291~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said tumor tissue is breast.
- 6 ~~292~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said tumor tissue is colon.
- 7 ~~293~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said tumor tissue is lung.
- 8 ~~294~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said tumor tissue is skin.
- 9 ~~295~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said tumor tissue is a carcinoma.
- 10 ~~296~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said tumor tissue is a melanoma.
- 11 ~~297~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering comprises intravenous administration.
- 12 ~~298~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering comprises oral administration.
- 13 ~~299~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering comprises transdermal administration.
- 14 ~~300~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering comprises intramuscular administration.
- 15 ~~301~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering comprises subcutaneous administration.
- 16 ~~302~~. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering comprises intracavity administration.

- 17 303. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering comprises peristaltic administration.
- 18 304. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering comprises parenteral administration.
- 19 305. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering comprises systemic administration.
- 20 306. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering comprises administration by gradual infusion.
- 21 307. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering comprises one or more dose administrations daily, for one or several days.
- 22 308. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering comprises a single dose.
- 23 309. (new) The method of claim ~~287~~ or ~~288~~ wherein said amount is from about 0.1 mg/kg to about 300 mg/kg patient body weight.
- 24 310. (new) The method of claim ~~287~~ or ~~288~~ wherein said amount is from about 0.2 mg/kg to about 200 mg/kg patient body weight.
- 25 311. (new) The method of claim ~~287~~ or ~~288~~ wherein said amount is from about 0.5 mg/kg to about 20 mg/kg patient body weight.
- 26 312. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering is conducted in conjunction with chemotherapy.
- 27 313. (new) The method of claim ~~287~~ or ~~288~~ wherein the patient is human.
- 28 314. (new) The method of claim ~~287~~ or ~~288~~ wherein the patient is a patient with angiofibromas.
- 29 315. (new) The method of claim ~~287~~ or ~~288~~ wherein the patient is a patient with retrolental fibroplasia.
- 30 316. (new) The method of claim ~~287~~ or ~~288~~ wherein the patient is a patient with hemangiomas.
- 31 317. (new) The method of claim ~~287~~ or ~~288~~ wherein the patient is a patient with Kaposi sarcoma.
- 32 318. (new) The method of claim ~~287~~ or ~~288~~ wherein said antibody preferentially inhibits fibrinogen binding to  $\alpha_v\beta_3$  compared to fibrinogen binding to  $\alpha_{IIb}\beta_3$ .

3219. (new) The method of claim ~~287~~ or ~~288~~ wherein said antibody specifically binds  $\alpha_v\beta_3$  complex.
3220. (new) The method of claim ~~287~~ or ~~288~~ wherein said antibody is an antibody fragment.
3221. (new) The method of claim ~~320~~ wherein said antibody is a Fab fragment.
3222. (new) The method of claim ~~320~~ wherein said antibody is a Fab' fragment.
3223. (new) The method of claim ~~320~~ wherein said antibody is a F(ab')<sub>2</sub> fragment.
3224. (new) The method of claim ~~320~~ wherein said antibody is a F(v) fragment.
3225. (new) The method of claim ~~288~~ wherein said monoclonal antibody has the binding specificity of the monoclonal antibody LM609 having ATCC accession number HB 9537.
3226. (new) The method of claim ~~288~~ wherein said monoclonal antibody is humanized.
3227. (new) The method of claim ~~287~~ or ~~288~~ wherein said tumor tissue is metastatic.
3228. (new) The method of claim ~~287~~ or ~~288~~ wherein said antibody is administered in a composition.
3229. (new) The method of claim ~~328~~ wherein said composition is a sterile pharmaceutical composition.
3230. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering is conducted following surgery.
3231. (new) The method of claim ~~287~~ or ~~288~~ wherein said patient was previously treated for a first tumor.
3232. (new) The method of claim ~~321~~ wherein said first tumor is a solid tumor.
3233. (new) The method of claim ~~321~~ wherein said first tumor is a carcinoma.
3234. (new) The method of claim ~~321~~ wherein said first tumor is a melanoma.
3235. (new) The method of claim ~~321~~ wherein said patient previously underwent surgery to remove said first tumor.
3236. (new) The method of claim ~~321~~ wherein said patient was previously treated with chemotherapy.
3237. (new) A method of inducing solid tumor tissue regression in a human patient in need thereof, said method comprising administering to said human patient a therapeutically effective amount of a humanized monoclonal antibody immunospecific for  $\alpha_v\beta_3$  complex.
3238. (new) The method of claim ~~327~~ wherein said humanized monoclonal antibody has the

binding specificity of the monoclonal antibody LM609 having ATCC accession number HB9537.

- F1*  
*Sub H1*
- ~~5339.~~ (new) The method of claim ~~337~~<sup>51</sup> or ~~338~~<sup>52</sup> wherein said tumor tissue is a melanoma.
- ~~5340.~~ (new) The method of claim ~~337~~<sup>51</sup> or ~~338~~<sup>52</sup> wherein said tumor tissue is a carcinoma.
- ~~5341.~~ (new) The method of claim ~~337~~<sup>51</sup> or ~~338~~<sup>52</sup> wherein said tumor tissue is a skin carcinoma solid tissue tumor.
- ~~5342.~~ (new) The method of claim ~~337~~<sup>51</sup> or ~~338~~<sup>52</sup> wherein said tumor tissue is a bladder carcinoma solid tissue tumor.
- ~~5343.~~ The method of claim ~~337~~<sup>51</sup> or ~~338~~<sup>52</sup> wherein said tumor tissue is a breast carcinoma solid tissue tumor.
- ~~5344.~~ The method of claim ~~337~~<sup>51</sup> or ~~338~~<sup>52</sup> wherein said tumor tissue is a colon carcinoma solid tissue tumor.
- ~~5345.~~ The method of claim ~~337~~<sup>51</sup> or ~~338~~<sup>52</sup> wherein said tumor tissue is a lung carcinoma solid tissue tumor.